Mucosal immunology of HIV infection

Immunological Reviews

Volumn 254, Issue 1, 2013, Pages 10-33

  Xu, Huanbin ^a   Wang, Xiaolei ^a   Veazey, Ronald S ^a  

^a TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

Author keywords

HIV; Mucosal immunology; SIV; T cell

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; DISEASE TRANSMISSION; ENTERIC VIRUS; GASTROINTESTINAL MUCOSA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNE SYSTEM; INNATE IMMUNITY; INTESTINE FLORA; LYMPHOID TISSUE; MEMORY T LYMPHOCYTE; MUCOSA; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SIMIAN IMMUNODEFICIENCY VIRUS; TARGET CELL; TH1 CELL; TH17 CELL; TH2 CELL; VAGINA MUCOSA; VIRUS REPLICATION; VIRUS STRAIN;

AIDS VACCINES; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; GASTROINTESTINAL TRACT; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, HUMORAL; IMMUNITY, INNATE; IMMUNITY, MUCOSAL; MUCOUS MEMBRANE; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VAGINA;

EID: 84879319982     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12072     Document Type: Article

References (270)

1. Granich R, Williams B, Montaner J. Fifteen million people on antiretroviral treatment by 2015: treatment as prevention. Curr Opin HIV AIDS 2013;8:41-49.
2. Shattock RJ, Warren M, McCormack S, Hankins CA. AIDS. Turning the tide against HIV. Science 2011;333:42-43.
3. Haynes BF, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012;366:1275-1286.
4. Rerks-Ngarm S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009;361:2209-2220.
5. Mofenson LM. Interaction between timing of perinatal human immunodeficiency virus infection and the design of preventive and therapeutic interventions. Acta Paediatr Suppl 1997;421:1-9.
6. Ruprecht RM, et al. Oral transmission of primate lentiviruses. J Infect Dis 1999;179(Suppl.):S408-S412.
7. Ruprecht RM, et al. Oral SIV, SHIV, and HIV type 1 infection. AIDS Res Hum Retroviruses 1998;14(Suppl):S97-S103.
8. Miclat NN, Hodgkinson R, Marx GF. Neonatal gastric pH. Anesth Analg 1978;57:98-101.
9. Miller CJ, et al. Genital mucosal transmission of simian immunodeficiency virus: animal model for heterosexual transmission of human immunodeficiency virus. J Virol 1989;63:4277-4284.
10. Ma ZM, et al. SIVmac251 is inefficiently transmitted to rhesus macaques by penile inoculation with a single SIVenv variant found in ramp-up phase plasma. AIDS Res Hum Retroviruses 2011;27:1259-1269.
11. Miller CJ, Shattock RJ. Target cells in vaginal HIV transmission. Microbes Infect 2003;5:59-67.
12. Marx PA, et al. Progesterone implants enhance SIV vaginal transmission and early virus load. Nat Med 1996;2:1084-1089.
13. Veazey RS, Shattock RJ, Klasse PJ, Moore JP. Animal models for microbicide studies. Curr HIV Res 2012;10:79-87.
14. Heffron R, et al. Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis 2012;12:19-26.
15. Wira CR, Patel MV, Ghosh M, Mukura L, Fahey JV. Innate immunity in the human female reproductive tract: endocrine regulation of endogenous antimicrobial protection against HIV and other sexually transmitted infections. Am J Reprod Immunol 2011;65:196-211.
16. Li Q, et al. Glycerol monolaurate prevents mucosal SIV transmission. Nature 2009;458:1034-1038.
17. Hughes JP, et al. Determinants of per-coital-act HIV-1 infectivity among African HIV-1-serodiscordant couples. J Infect Dis 2012;205:358-365.
18. Shukair SA, et al. Human cervicovaginal mucus contains an activity that hinders HIV-1 movement. Mucosal Immunol 2013;6:427-434.
19. Mauck CK, et al. The effect of one injection of Depo-Provera on the human vaginal epithelium and cervical ectopy. Contraception 1999;60:15-24.
20. Poonia B, Walter L, Dufour J, Harrison R, Marx PA, Veazey RS. Cyclic changes in the vaginal epithelium of normal rhesus macaques. J Endocrinol 2006;190:829-835.
21. Ma Z, Lu FX, Torten M, Miller CJ. The number and distribution of immune cells in the cervicovaginal mucosa remain constant throughout the menstrual cycle of rhesus macaques. Clin Immunol 2001;100:240-249.
22. Poonia B, Wang X, Veazey RS. Distribution of simian immunodeficiency virus target cells in vaginal tissues of normal rhesus macaques: implications for virus transmission. J Reprod Immunol 2006;72:74-84.
23. Sodora DL, Gettie A, Miller CJ, Marx PA. Vaginal transmission of SIV: assessing infectivity and hormonal influences in macaques inoculated with cell-free and cell-associated viral stocks. AIDS Res Human Retroviruses 1998;14(Suppl):S119-S123.
24. Vishwanathan SA, et al. High susceptibility to repeated, low-dose, vaginal SHIV exposure late in the luteal phase of the menstrual cycle of pigtail macaques. J Acquir Immune Defic Syndr 2011;57:261-264.
25. Wira CR, Fahey JV, Abrahams VM, Rossoll RM. Influence of stage of the reproductive cycle and estradiol on thymus cell antigen presentation. J Steroid Biochem Mol Biol 2003;84:79-87.
26. Wira CR, Fahey JV, Sentman CL, Pioli PA, Shen L. Innate and adaptive immunity in female genital tract: cellular responses and interactions. Immunol Rev 2005;206:306-335.
27. Mascola JR, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000;6:207-210.
28. Veazey RS, et al. Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection. J Exp Med 2003;198:1551-1562.
29. Veazey RS, et al. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med 2003;9:343-346.
30. Hu J, Gardner MB, Miller CJ. Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells. J Virol 2000;74:6087-6095.
31. Hu J, Pope M, Brown C, O'Doherty U, Miller CJ. Immunophenotypic characterization of simian immunodeficiency virus- infected dendritic cells in cervix, vagina, and draining lymph nodes of rhesus monkeys. Lab Invest 1998;78:435-451.
32. Hussain LA, Lehner T. Comparative investigation of Langerhans' cells and potential receptors for HIV in oral, genitourinary and rectal epithelia. Immunology 1995;85:475-484.
33. Bjercke S, Scott H, Braathen LR, Thorsby E. HLA-DR-expressing Langerhans'-like cells in vaginal and cervical epithelium. Acta Obstet Gynecol Scand 1983;62:585-589.
34. Morris HH, Gatter KC, Stein H, Mason DY. Langerhans' cells in human cervical epithelium: an immunohistological study. Br J Obstet Gyn 1983;90:400-411.
35. Turville SG, et al. Immunodeficiency virus uptake, turnover, and 2-phase transfer in human dendritic cells. Blood 2004;103:2170-2179.
36. Miller CJ, McChesney M, Moore PF. Langerhans cells, macrophages, and lymphocyte subsets in the cervix and vagina of rhesus macaques. Lab Invest 1992;67:628-634.
37. Geijtenbeek TB, et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 2000;100:587-597.
38. Turville SG, et al. Diversity of receptors binding HIV on dendritic cell subsets. Nat Immunol 2002;3:975-983.
39. Baribaud F, Pohlmann S, Doms RW. The role of DC-SIGN and DC-SIGNR in HIV and SIV attachment, infection, and transmission. Virology 2001;286:1-6.
40. Hu Q, et al. Blockade of attachment and fusion receptors inhibits HIV-1 infection of human cervical tissue. J Exp Med 2004;199:1065-1075.
41. Parr MB, Kepple L, Parr EL. Antigen recognition in the female reproductive tract. II. Endocytosis of horseradish peroxidase by Langerhans cells in murine vaginal epithelium. Biology Reprod 1991;45:261-265.
42. Veazey RS, Marx PA, Lackner AA. Vaginal CD4+ T cells express high levels of CCR5 and are rapidly depleted in simian immunodeficiency virus infection. J Infect Dis 2003;187:769-776.
43. Haase AT. Early events in sexual transmission of HIV and SIV and opportunities for interventions. Annu Rev Med 2011;62:127-139.
44. Shattock RJ, Moore JP. Inhibiting sexual transmission of HIV-1 infection. Nat Rev Microbiol 2003;1:25-34.
45. Miller CJ, et al. Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. J Virol 2005;79:9217-9227.
46. Zhang Z, et al. Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science 1999;286:1353-1357.
47. Salazar-Gonzalez JF, et al. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med 2009;206:1273-1289.
48. Keele BF, Derdeyn CA. Genetic and antigenic features of the transmitted virus. Curr Opin HIV AIDS 2009;4:352-357.
49. Blaskewicz CD, Pudney J, Anderson DJ. Structure and function of intercellular junctions in human cervical and vaginal mucosal epithelia. Biol Reprod 2011;85:97-104.
50. Pandrea I, et al. Mucosal simian immunodeficiency virus transmission in African green monkeys: susceptibility to infection is proportional to target cell availability at mucosal sites. J Virol 2012;86:4158-4168.
51. Keele BF, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA 2008;105:7552-7557.
52. Hladik F, et al. Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity 2007;26:257-270.
53. Veazey RS, et al. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature 2005;438:99-102.
54. Veazey RS, et al. Tropism-independent protection of macaques against vaginal transmission of three SHIVs by the HIV-1 fusion inhibitor T-1249. Proc Natl Acad Sci USA 2008;105:10531-10536.
55. Veazey RS, et al. Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor. J Infect Dis 2010;202:739-744.
56. Veazey RS, et al. Topically applied recombinant chemokine analogues fully protect macaques from vaginal simian-human immunodeficiency virus challenge. J Infect Dis 2009;199:1525-1527.
57. Lederman MM, et al. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 2004;306:485-487.
58. Schust DJ, Quayle AJ, Amedee AM. Mucosal co-infections and HIV-1 transmission and pathogenesis. Curr HIV Res 2012;10:195-201.
59. Cohen CR, et al. Increased interleukin-10 in the the endocervical secretions of women with non-ulcerative sexually transmitted diseases: a mechanism for enhanced HIV-1 transmission? AIDS 1999;13:327-332.
60. Mayer KH, Venkatesh KK. Interactions of HIV, other sexually transmitted diseases, and genital tract inflammation facilitating local pathogen transmission and acquisition. Am J Reprod Immunol 2011;65:308-316.
61. Schust DJ, et al. Potential mechanisms for increased HIV-1 transmission across the endocervical epithelium during C. trachomatis infection. Curr HIV Res 2012;10:218-227.
62. Jameson B, et al. Expression of DC-SIGN by dendritic cells of intestinal and genital mucosae in humans and rhesus macaques. J Virol 2002;76:1866-1875.
63. Bhoopat L, et al. In vivo identification of Langerhans and related dendritic cells infected with HIV-1 subtype E in vaginal mucosa of asymptomatic patients. Mod Pathol 2001;14:1263-1269.
64. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010;140:805-820.
65. Srikrishna G, Freeze HH. Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer. Neoplasia 2009;11:615-628.
66. Mogensen TH, Melchjorsen J, Larsen CS, Paludan SR. Innate immune recognition and activation during HIV infection. Retrovirology 2010;7:54.
67. Pivarcsi A, et al. Microbial compounds induce the expression of pro-inflammatory cytokines, chemokines and human beta-defensin-2 in vaginal epithelial cells. Microbes Infect 2005;7:1117-1127.
68. Herbst-Kralovetz MM, et al. Quantification and comparison of toll-like receptor expression and responsiveness in primary and immortalized human female lower genital tract epithelia. Am J Reprod Immunol 2008;59:212-224.
69. Han JH, et al. Modulation of human beta-defensin-2 expression by 17beta-estradiol and progesterone in vaginal epithelial cells. Cytokine 2010;49:209-214.
70. Cole AM, Cole AL. Antimicrobial polypeptides are key anti-HIV-1 effector molecules of cervicovaginal host defense. Am J Reprod Immunol 2008;59:27-34.
71. Rancez M, Couedel-Courteille A, Cheynier R. Chemokines at mucosal barriers and their impact on HIV infection. Cytokine Growth Factor Rev 2012;23:233-243.
72. Cremel M, et al. Characterization of CCL20 secretion by human epithelial vaginal cells: involvement in Langerhans cell precursor attraction. J Leukoc Biol 2005;78:158-166.
73. Dieu-Nosjean MC, et al. Macrophage inflammatory protein 3alpha is expressed at inflamed epithelial surfaces and is the most potent chemokine known in attracting Langerhans cell precursors. J Exp Med 2000;192:705-718.
74. Wang Y, Abel K, Lantz K, Krieg AM, McChesney MB, Miller CJ. The Toll-like receptor 7 (TLR7) agonist, imiquimod, and the TLR9 agonist, CpG ODN, induce antiviral cytokines and chemokines but do not prevent vaginal transmission of simian immunodeficiency virus when applied intravaginally to rhesus macaques. J Virol 2005;79:14355-14370.
75. de Jong MA, de Witte L, Oudhoff MJ, Gringhuis SI, Gallay P, Geijtenbeek TB. TNF-alpha and TLR agonists increase susceptibility to HIV-1 transmission by human Langerhans cells ex vivo. J Clin Invest 2008;118:3440-3452.
76. Abel K, Rocke DM, Chohan B, Fritts L, Miller CJ. Temporal and anatomic relationship between virus replication and cytokine gene expression after vaginal simian immunodeficiency virus infection. J Virol 2005;79:12164-12172.
77. Shacklett BL, Anton PA. HIV infection and gut mucosal immune function: updates on pathogenesis with implications for management and intervention. Curr Infect Dis Rep 2010;12:19-27.
78. Ling B, et al. The large intestine as a major reservoir for simian immunodeficiency virus in macaques with long-term, nonprogressing infection. J Infect Dis 2010;202:1846-1854.
79. Veazey RS, Marx PA, Lackner AA. The mucosal immune system: primary target for HIV infection and AIDS. Trends Immunol 2001;22:626-633.
80. Veazey RS, et al. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science 1998;280:427-431.
81. Smit-McBride Z, Mattapallil JJ, McChesney M, Ferrick D, Dandekar S. Gastrointestinal T lymphocytes retain high potential for cytokine responses but have severe CD4+ T-cell depletion at all stages of simian immunodeficiency virus infection compared to peripheral lymphocytes. J Virol 1998;72:6646-6656.
82. Guadalupe M, et al. Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol 2003;77:11708-11717.
83. Brenchley JM, et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 2004;200:749-759.
84. Mattapallil JJ, Douek DC, Hill B, Nishimura Y, Martin M, Roederer M. Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature 2005;434:1093-1097.
85. Picker LJ, Hansen SG, Lifson JD. New paradigms for HIV/AIDS vaccine development. Annu Rev Med 2012;63:95-111.
86. Fukata M, Vamadevan AS, Abreu MT. Toll-like receptors (TLRs) and Nod-like receptors (NLRs) in inflammatory disorders. Semin Immunol 2009;21:242-253.
87. Shang L, et al. Toll-like receptor signaling in small intestinal epithelium promotes B-cell recruitment and IgA production in lamina propria. Gastroenterology 2008;135:529-538.
88. Cario E, Gerken G, Podolsky DK. Toll-like receptor 2 enhances ZO-1-associated intestinal epithelial barrier integrity via protein kinase C. Gastroenterology 2004;127:224-238.
89. Girardin SE, et al. Nod1 detects a unique muropeptide from gram-negative bacterial peptidoglycan. Science 2003;300:1584-1587.
90. Bouskra D, et al. Lymphoid tissue genesis induced by commensals through NOD1 regulates intestinal homeostasis. Nature 2008;456:507-510.
91. Stecher B, et al. Salmonella enterica serovar typhimurium exploits inflammation to compete with the intestinal microbiota. PLoS Biol 2007;5:2177-2189.
92. Endt K, et al. The microbiota mediates pathogen clearance from the gut lumen after non-typhoidal Salmonella diarrhea. PLoS Pathog 2010;6:e1001097.
93. Simmons CP, et al. Central role for B lymphocytes and CD4+ T cells in immunity to infection by the attaching and effacing pathogen Citrobacter rodentium. Infect Immun 2003;71:5077-5086.
94. Zheng Y, et al. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Med 2008;14:282-289.
95. Harrison OJ, Maloy KJ. Innate immune activation in intestinal homeostasis. J Innate Immun 2011;3:585-593.
96. Blaschitz C, Raffatellu M. Th17 cytokines and the gut mucosal barrier. J Clin Immunol 2010;30:196-203.
97. Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 2006;6:148-158.
98. Veazey R, Lackner A. The mucosal immune system and HIV-1 infection. AIDS Rev 2003;5:245-252.
99. Veazey RS, et al. Dynamics of CCR5 expression by CD4(+) T cells in lymphoid tissues during simian immunodeficiency virus infection. J Virol 2000;74:11001-11007.
100. Fauci AS, Pantaleo G, Stanley S, Weissman D. Immunopathogenic mechanisms of HIV infection. Ann Intern Med 1996;124:654-663.
101. Deeks SG, Walker BD. The immune response to AIDS virus infection: good, bad, or both? J Clin Invest 2004;113:808-810.
102. Giorgi JV, et al. Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection. J Acquir Immune Defic Syndr 2002;29:346-355.
103. Silvestri G, et al. Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia. Immunity 2003;18:441-452.
104. Silvestri G, Paiardini M, Pandrea I, Lederman MM, Sodora DL. Understanding the benign nature of SIV infection in natural hosts. J Clin Invest 2007;117:3148-3154.
105. Kornfeld C, et al. Antiinflammatory profiles during primary SIV infection in African green monkeys are associated with protection against AIDS. J Clin Invest 2005;115:1082-1091.
106. Pandrea I, et al. Simian immunodeficiency virus SIVagm.sab infection of Caribbean African green monkeys: a new model for the study of SIV pathogenesis in natural hosts. J Virol 2006;80:4858-4867.
107. Douek DC, Picker LJ, Koup RA. T cell dynamics in HIV-1 infection. Annu Rev Immunol 2003;21:265-304.
108. Sachsenberg N, et al. Turnover of CD4+ and CD8+ T lymphocytes in HIV-1 infection as measured by Ki-67 antigen. J Exp Med 1998;187:1295-1303.
109. Mohri H, Bonhoeffer S, Simon M, Perelson AS, Ho DD. Rapid turnover of T lymphocytes in SIV-infected rhesus macaques. Science 1998;279:1223-1227.
110. Combadere B, et al. CD4+Ki67+ lymphocytes in HIV-infected patients are effector T cells accumulated in the G1 phase of the cell cycle. Eur J Immunol 2000;30:3598-3603.
111. Benecke A, Gale M Jr, Katze MG. Dynamics of innate immunity are key to chronic immune activation in AIDS. Curr Opin HIV AIDS 2012;7:79-85.
112. Porichis F, Kaufmann DE. Role of PD-1 in HIV pathogenesis and as target for therapy. Curr HIV/AIDS Rep 2012;9:81-90.
113. Yue FY, et al. Preferential apoptosis of HIV-1-specific CD4+ T cells. J Immunol 2005;174:2196-2204.
114. Xu H, Wang X, Morici LA, Pahar B, Veazey RS. Early divergent host responses in SHIVsf162P3 and SIVmac251 infected macaques correlate with control of viremia. PLoS ONE 2011;6:e17965.
115. Keating SM, Jacobs ES, Norris PJ. Soluble mediators of inflammation in HIV and their implications for therapeutics and vaccine development. Cytokine Growth Factor Rev 2012;23:193-206.
116. Brenchley JM, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006;12:1365-1371.
117. Sandler NG, Douek DC. Microbial translocation in HIV infection: causes, consequences and treatment opportunities. Nat Rev Microbiol 2012;10:655-666.
118. Schacker TW, et al. Lymphatic tissue fibrosis is associated with reduced numbers of naive CD4+ T cells in human immunodeficiency virus type 1 infection. Clin Vaccine Immunol 2006;13:556-560.
119. Brenchley JM, et al. Differential Th17 CD4 T cell depletion in pathogenic and nonpathogenic lentiviral infections. Blood 2008;112:2826-2835.
120. Estes JD, et al. Damaged intestinal epithelial integrity linked to microbial translocation in pathogenic simian immunodeficiency virus infections. PLoS Pathog 2010;6:e1001052.
121. Sodora DL, Silvestri G. Immune activation and AIDS pathogenesis. AIDS 2008;22:439-446.
122. Wang X, et al. Simian immunodeficiency virus selectively infects proliferating CD4+ T cells in neonatal rhesus macaques. Blood 2010;116:4168-4174.
123. Schacker TW, et al. Persistent abnormalities in lymphoid tissues of human immunodeficiency virus-infected patients successfully treated with highly active antiretroviral therapy. J Infect Dis 2002;186:1092-1097.
124. Estes J, et al. Collagen deposition limits immune reconstitution in the gut. J Infect Dis 2008;198:456-464.
125. Nazli A, et al. Exposure to HIV-1 directly impairs mucosal epithelial barrier integrity allowing microbial translocation. PLoS Pathog 2010;6:e1000852.
126. Douek DC, et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature 2002;417:95-98.
127. Veazey RS. Mucosal immunopathogenesis of HIV infection: implications for vaccine development. Future HIV Ther 2007;1:103-112.
128. Handley SA, et al. Pathogenic simian immunodeficiency virus infection is associated with expansion of the enteric virome. Cell 2012;151:253-266.
129. Veazey RS, Lackner AA. Getting to the guts of HIV pathogenesis. J Exp Med 2004;200:697-700.
130. Veazey RS, et al. Identifying the target cell in primary simian immunodeficiency virus (SIV) infection: highly activated memory CD4(+) T cells are rapidly eliminated in early SIV infection in vivo. J Virol 2000;74:57-64.
131. Mehandru S, et al. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med 2004;200:761-770.
132. Mosmann TR, Kobie JJ, Lee FE, Quataert SA. T helper cytokine patterns: defined subsets, random expression, and external modulation. Immunol Res 2009;45:173-184.
133. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986;136:2348-2357.
134. Walker JA, Barlow JL, McKenzie AN. Innate lymphoid cells - how did we miss them? Nat Rev Immunol 2013;13:75-87.
135. McMichael AJ, Borrow P, Tomaras GD, Goonetilleke N, Haynes BF. The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol 2010;10:11-23.
136. Klein SA, et al. Demonstration of the Th1 and Th2 cytokine shift during the course of HIV-1 infection using cytoplasmic cytokine detection on single cell level by flow cytometry. AIDS 1997;11:1111-1118.
137. Bostik P, Watkins M, Villinger F, Ansari AA. Genetic analysis of cytokine promoters in nonhuman primates: implications for Th1/Th2 profile characteristics and SIV disease pathogenesis. Clin Dev Immunol 2004;11:35-44.
138. Stylianou E, Aukrust P, Kvale D, Muller F, Froland SS. IL-10 in HIV infection: increasing serum IL-10 levels with disease progression-down-regulatory effect of potent anti-retroviral therapy. Clin Exp Immunol 1999;116:115-120.
139. Benveniste O, et al. Comparative interleukin (IL)-2/interferon (IFN)-g and IL-4/IL-10 responses during acute infection of macaques inoculated with attenuated nef-truncated or pathogenic SIVmac251 virus. Proc Natl Acad Sci USA 1996;93:3658-3663.
140. Li Y, Ling W, Xu H, Wang M, Wu C. The activation and dynamics of cytokine expression by CD4+ T cells and AIDS progression in HIV-1-infected Chinese individuals. Microb Pathog 2012;53:189-197.
141. Bahbouhi B, Landay A, Al-Harthi L. Dynamics of cytokine expression in HIV productively infected primary CD4+ T cells. Blood 2004;103:4581-4587.
142. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol 2009;27:485-517.
143. Ivanov II, et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 2009;139:485-498.
144. Zaph C, et al. Commensal-dependent expression of IL-25 regulates the IL-23-IL-17 axis in the intestine. J Exp Med 2008;205:2191-2198.
145. Mayuzumi H, Inagaki-Ohara K, Uyttenhove C, Okamoto Y, Matsuzaki G. Interleukin-17A is required to suppress invasion of Salmonella enterica serovar Typhimurium to enteric mucosa. Immunology 2010;131:377-385.
146. Santaolalla R, Abreu MT. Innate immunity in the small intestine. Curr Opin Gastroenterol 2012;28:124-129.
147. Favre D, et al. Critical loss of the balance between Th17 and T regulatory cell populations in pathogenic SIV infection. PLoS Pathog 2009;5:e1000295.
148. Cecchinato V, Franchini G. Th17 cells in pathogenic simian immunodeficiency virus infection of macaques. Curr Opin HIV AIDS 2010;5:141-145.
149. Klatt NR, Brenchley JM. Th17 cell dynamics in HIV infection. Curr Opin HIV AIDS 2010;5:135-140.
150. Cecchinato V, et al. Altered balance between Th17 and Th1 cells at mucosal sites predicts AIDS progression in simian immunodeficiency virus-infected macaques. Mucosal Immunol 2008;1:279-288.
151. Xu H, Wang X, Liu DX, Moroney-Rasmussen T, Lackner AA, Veazey RS. IL-17-producing innate lymphoid cells are restricted to mucosal tissues and are depleted in SIV-infected macaques. Mucosal Immunol 2012;5:658-669.
152. Hartigan-O'connor DJ, Hirao LA, McCune JM, Dandekar S. Th17 cells and regulatory T cells in elite control over HIV and SIV. Curr Opin HIV AIDS 2011;6:221-227.
153. Brandt L, et al. Low level of regulatory T-cells and maintenance of balance between regulatory T-cells and TH17 cells in HIV-1-infected elite controllers. J Acquir Immune Defic Syndr 2011;57:101-108.
154. Ciccone EJ, et al. CD4+ T cells, including Th17 and cycling subsets, are intact in the gut mucosa of HIV-1 infected long-term non-progressors. J Virol 2011;85:5880-5888.
155. Campbell DJ, Koch MA. Phenotypical and functional specialization of FOXP3+ regulatory T cells. Nat Rev Immunol 2011;11:119-130.
156. Schulze Zur Wiesch J, et al. Comprehensive analysis of frequency and phenotype of T regulatory cells in HIV infection: CD39 expression of FoxP3+ T regulatory cells correlates with progressive disease. J Virol 2011;85:1287-1297.
157. Boasso A, et al. Regulatory T-cell markers, indoleamine 2, 3-dioxygenase, and virus levels in spleen and gut during progressive simian immunodeficiency virus infection. J Virol 2007;81:11593-11603.
158. Aandahl EM, Michaelsson J, Moretto WJ, Hecht FM, Nixon DF. Human CD4+ CD25+ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. J Virol 2004;78:2454-2459.
159. Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, Schoenberger SP. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 2003;421:852-856.
160. Sun JC, Bevan MJ. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 2003;300:339-342.
161. Shedlock DJ, Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 2003;300:337-339.
162. MacLennan IC. Somatic mutation. From the dark zone to the light. Curr Biol 1994;4:70-72.
163. Liu YJ, Grouard G, de Bouteiller O, Banchereau J. Follicular dendritic cells and germinal centers. Int Rev Cytol 1996;166:139-179.
164. King C, Sprent J. Emerging cellular networks for regulation of T follicular helper cells. Trends Immunol 2012;33:59-65.
165. Crotty S. Follicular helper CD4 T cells (TFH). Annu Rev Immunol 2011;29:621-663.
166. Yu D, Vinuesa CG. The elusive identity of T follicular helper cells. Trends Immunol 2010;31:377-383.
167. Johnston RJ, et al. Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation. Science 2009;325:1006-1010.
168. Lindqvist M, et al. Expansion of HIV-specific T follicular helper cells in chronic HIV infection. J Clin Invest 2012;122:3271-3280.
169. Petrovas C, et al. CD4 T follicular helper cell dynamics during SIV infection. J Clin Invest 2012;122:3281-3294.
170. Hong JJ, Amancha PK, Rogers K, Ansari AA, Villinger F. Spatial alterations between CD4(+) T follicular helper, B, and CD8(+) T cells during simian immunodeficiency virus infection: T/B cell homeostasis, activation, and potential mechanism for viral escape. J Immunol 2012;188:3247-3256.
171. Perreau M, et al. Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production. J Exp Med 2013;210:143-156.
172. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994;68:6103-6110.
173. Koup RA, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994;68:4650-4655.
174. Wilson JD, et al. Direct visualization of HIV-1-specific cytotoxic T lymphocytes during primary infection. AIDS 2000;14:225-233.
175. Reynolds MR, et al. CD8+ T-lymphocyte response to major immunodominant epitopes after vaginal exposure to simian immunodeficiency virus: too late and too little. J Virol 2005;79:9228-9235.
176. Schmitz JE, et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999;283:857-860.
177. Klatt NR, et al. CD8+ lymphocytes control viral replication in SIVmac239-infected rhesus macaques without decreasing the lifespan of productively infected cells. PLoS Pathog 2010;6:e1000747.
178. Reynolds MR, et al. Macaques vaccinated with live-attenuated SIV control replication of heterologous virus. J Exp Med 2008;205:2537-2550.
179. Veazey RS, et al. Emergence and kinetics of simian immunodeficiency virus-specific CD8(+) T cells in the intestines of macaques during primary infection. J Virol 2001;75:10515-10519.
180. Brennan TP, Woods JO, Sedaghat AR, Siliciano JD, Siliciano RF, Wilke CO. Analysis of human immunodeficiency virus type 1 viremia and provirus in resting CD4+ T cells reveals a novel source of residual viremia in patients on antiretroviral therapy. J Virol 2009;83:8470-8481.
181. Veazey RS, et al. Dynamics of Simian immunodeficiency virus-specific cytotoxic T-cell responses in tissues. J Med Primatol 2003;32:194-200.
182. Belyakov IM, Ahlers JD, Nabel GJ, Moss B, Berzofsky JA. Generation of functionally active HIV-1 specific CD8+ CTL in intestinal mucosa following mucosal, systemic or mixed prime-boost immunization. Virology 2008;381:106-115.
183. Kaul R, et al. Quantitative ex vivo analysis of functional virus-specific CD8 T lymphocytes in the blood and genital tract of HIV-infected women. AIDS 2003;17:1139-1144.
184. Kaul R, et al. HIV-1-specific mucosal CD8+ lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi. J Immunol 2000;164:1602-1611.
185. Mendiratta S, Vajpayee M, Mojumdar K, Chauhan NK, Sreenivas V. Polyfunctional analysis of Gag and Nef specific CD8+ T-cell responses in HIV-1 infected Indian individuals. Vaccine 2011;29:1150-1158.
186. Goonetilleke N, et al. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med 2009;206:1253-1272.
187. Turnbull EL, et al. Kinetics of expansion of epitope-specific T cell responses during primary HIV-1 infection. J Immunol 2009;182:7131-7145.
188. Allen TM, et al. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viremia. Nature 2000;407:386-390.
189. Picker LJ. Immunopathogenesis of acute AIDS virus infection. Curr Opin Immunol 2006;18:399-405.
190. Kaech SM, Wherry EJ. Heterogeneity and cell-fate decisions in effector and memory CD8+ T cell differentiation during viral infection. Immunity 2007;27:393-405.
191. Williams MA, Bevan MJ. Effector and memory CTL differentiation. Annu Rev Immunol 2007;25:171-192.
192. Arens R, Schoenberger SP. Plasticity in programming of effector and memory CD8 T-cell formation. Immunol Rev 2010;235:190-205.
193. Masopust D, Kaech SM, Wherry EJ, Ahmed R. The role of programming in memory T-cell development. Curr Opin Immunol 2004;16:217-225.
194. Wherry EJ, et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 2007;27:670-684.
195. Fuller MJ, Zajac AJ. Ablation of CD8 and CD4 T cell responses by high viral loads. J Immunol 2003;170:477-486.
196. Shin H, et al. A role for the transcriptional repressor Blimp-1 in CD8(+) T cell exhaustion during chronic viral infection. Immunity 2009;31:309-320.
197. Blackburn SD, et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 2009;10:29-37.
198. Blackburn SD, Crawford A, Shin H, Polley A, Freeman GJ, Wherry EJ. Tissue-specific differences in PD-1 and PD-L1 expression during chronic viral infection: implications for CD8 T-cell exhaustion. J Virol 2010;84:2078-2089.
199. Ortiz AM, et al. Depletion of CD4(+) T cells abrogates post-peak decline of viremia in SIV-infected rhesus macaques. J Clin Invest 2011;121:4433-4445.
200. Jones NG, DeCamp A, Gilbert P, Peterson ML, Gurwith M, Cao H. AIDSVAX immunization induces HIV-specific CD8+ T-cell responses in high-risk, HIV-negative volunteers who subsequently acquire HIV infection. Vaccine 2009;27:1136-1140.
201. Crellin NK, Trifari S, Kaplan CD, Cupedo T, Spits H. Human NKp44+IL-22+ cells and LTi-like cells constitute a stable RORC+ lineage distinct from conventional natural killer cells. J Exp Med 2010;207:281-290.
202. Satoh-Takayama N, et al. IL-7 and IL-15 independently program the differentiation of intestinal CD3-NKp46+ cell subsets from Id2-dependent precursors. J Exp Med 2010;207:273-280.
203. Kanamori Y, et al. Identification of novel lymphoid tissues in murine intestinal mucosa where clusters of c-kit+ IL-7R+ Thy1+ lympho-hemopoietic progenitors develop. J Exp Med 1996;184:1449-1459.
204. Eberl G, Sawa S. Opening the crypt: current facts and hypotheses on the function of cryptopatches. Trends Immunol 2010;31:50-55.
205. Spits H, Di Santo JP. The expanding family of innate lymphoid cells: regulators and effectors of immunity and tissue remodeling. Nat Immunol 2011;12:21-27.
206. Tsuji NM, Kosaka A. Oral tolerance: intestinal homeostasis and antigen-specific regulatory T cells. Trends Immunol 2008;29:532-540.
207. Withers DR. Lymphoid tissue inducer cells. Curr Biol 2011;21:R381-R382.
208. Lane PJ, Kim MY, Gaspal FM, McConnell FM. CD4+CD3- cells regulate the organization of lymphoid tissue and T-cell memory for antibody responses. Int J Hematol 2006;83:12-16.
209. Sawa S, et al. RORgammat+ innate lymphoid cells regulate intestinal homeostasis by integrating negative signals from the symbiotic microbiota. Nat Immunol 2011;12:320-326.
210. Reeves RK, et al. Gut inflammation and indoleamine deoxygenase inhibit IL-17 production and promote cytotoxic potential in NKp44+ mucosal NK cells during SIV infection. Blood 2011;118:3321-3330.
211. Carrington M, Alter G. Innate immune control of HIV. Cold Spring Harb Perspect Med 2012;2:a007070.
212. Martin MP, et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 2002;31:429-434.
213. Cohen GB, et al. The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity 1999;10:661-671.
214. Shacklett BL. Understanding the "lucky few": the conundrum of HIV-exposed, seronegative individuals. Curr HIV/AIDS Rep 2006;3:26-31.
215. Embretson J, et al. Massive cohert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 1993;362:359-362.
216. Pantaleo G, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993;362:355-362.
217. Poles MA, et al. Lack of decay of HIV-1 in gut-associated lymphoid tissue reservoirs in maximally suppressed individuals. J Acquir Immune Defic Syndr 2006;43:65-68.
218. Manheimer-Lory AJ, Zandman-Goddard G, Davidson A, Aranow C, Diamond B. Lupus-specific antibodies reveal an altered pattern of somatic mutation. J Clin Invest 1997;100:2538-2546.
219. Zeng M, et al. Cumulative mechanisms of lymphoid tissue fibrosis and T cell depletion in HIV-1 and SIV infections. J Clin Invest 2011;121:998-1008.
220. Pantaleo G, Graziosi C, Fauci AS. The immunopathogenesis of human immunodeficiency virus infection. N Engl J Med 1993;328:327-335.
221. Zeng M, Haase AT, Schacker TW. Lymphoid tissue structure and HIV-1 infection: life or death for T cells. Trends Immunol 2012;33:306-314.
222. Levesque MC, et al. Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection. PLoS Med 2009;6:e1000107.
223. Dykhuizen M, et al. Determinants of disease in the simian immunodeficiency virus-infected rhesus macaque: characterizing animals with low antibody responses and rapid progression. J Gen Virol 1998;79:2461-2467.
224. Imagawa DT, et al. Human immunodeficiency virus type 1 infection in homosexual men who remain seronegative for prolonged periods. N Engl J Med 1989;320:1458-1462.
225. Michael NL, et al. Rapid disease progression without seroconversion following primary human immunodeficiency virus type 1 infection-evidence for highly susceptible human hosts. J Infect Dis 1997;175:1352-1359.
226. Tenner-Racz K, Racz P. Follicular dendritic cells initiate and maintain infection of the germinal centers by human immunodeficiency virus. Curr Top Microbiol Immunol 1995;201:141-159.
227. Langford TD, et al. Central importance of immunoglobulin A in host defense against Giardia spp. Infect Immun 2002;70:11-18.
228. Hapfelmeier S, et al. Reversible microbial colonization of germ-free mice reveals the dynamics of IgA immune responses. Science 2010;328:1705-1709.
229. Tsuji M, et al. Preferential generation of follicular B helper T cells from Foxp3+ T cells in gut Peyer's patches. Science 2009;323:1488-1492.
230. Stavnezer J, Kang J. The surprising discovery that TGF beta specifically induces the IgA class switch. J Immunol 2009;182:5-7.
231. Tsuji M, et al. Requirement for lymphoid tissue-inducer cells in isolated follicle formation and T cell-independent immunoglobulin A generation in the gut. Immunity 2008;29:261-271.
232. Wei X, et al. Antibody neutralization and escape by HIV-1. Nature 2003;422:307-312.
233. Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci USA 2003;100:4144-4149.
234. Zhang ZQ, et al. Early depletion of proliferating B cells of germinal center in rapidly progressive simian immunodeficiency virus infection. Virology 2007;361:455-464.
235. Alam SM, et al. Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection. J Virol 2008;82:115-125.
236. Mestecky J, Raska M, Novak J, Alexander RC, Moldoveanu Z. Antibody-mediated protection and the mucosal immune system of the genital tract: relevance to vaccine design. J Reprod Immunol 2010;85:81-85.
237. Russell MW, Mestecky J. Humoral immune responses to microbial infections in the genital tract. Microbes Infect 2002;4:667-677.
238. Moldoveanu Z, Huang WQ, Kulhavy R, Pate MS, Mestecky J. Human male genital tract secretions: both mucosal and systemic immune compartments contribute to the humoral immunity. J Immunol 2005;175:4127-4136.
239. Miller CJ, et al. Genital secretory immune response to chronic simian immunodeficiency virus (SIV) infection: a comparison between intravenously and genitally inoculated rhesus macaques. Clin Exp Immunol 1992;88:520-526.
240. Parren PW, et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 2001;75:8340-8347.
241. Baba TW, et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 2000;6:200-206.
242. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005;191:654-665.
243. McCarthy M. HIV vaccine fails in phase 3 trial. Lancet 2003;361:755-756.
244. Gray RH, Tobian A, Kigozi G, Wawer MJ, Serwadda D. Commentary: male circumcision for prevention of heterosexual acquisition of HIV in men: perspective from a trial team. Int J Epidemiol 2010;39:970-971.
245. Nicholson O, et al. Safety and immunogenicity of the MRKAd5 gag HIV type 1 vaccine in a worldwide phase 1 study of healthy adults. AIDS Res Hum Retroviruses 2011;27:557-567.
246. Staprans SI, et al. Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein. Proc Natl Acad Sci USA 2004;101:13026-13031.
247. McElrath MJ, Haynes BF. Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity 2010;33:542-554.
248. Bonsignori M, et al. Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol 2012;86:11521-11532.
249. Hansen SG, et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 2011;473:523-527.
250. Johnson RP, Desrosiers RC. Protective immunity induced by live attenuated simian immunodeficiency virus. Curr Opin Immunol 1998;10:436-443.
251. Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 1992;258:1938-1941.
252. Alpert MD, et al. ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIV(mac)251 challenge. PLoS Pathog 2012;8:e1002890.
253. Fukazawa Y, et al. Lymph node T cell responses predict the efficacy of live attenuated SIV vaccines. Nat Med 2012;18:1673-1681.
254. Patterson LJ, et al. Replicating adenovirus-simian immunodeficiency virus (SIV) vectors efficiently prime SIV-specific systemic and mucosal immune responses by targeting myeloid dendritic cells and persisting in rectal macrophages, regardless of immunization route. Clin Vaccine Immunol 2012;19:629-637.
255. Vargas-Inchaustegui DA, Xiao P, Tuero I, Patterson LJ, Robert-Guroff M. NK and CD4+ T cell cooperative immune responses correlate with control of disease in a macaque simian immunodeficiency virus infection model. J Immunol 2012;189:1878-1885.
256. Xiao P, et al. Replicating adenovirus-simian immunodeficiency virus (SIV) recombinant priming and envelope protein boosting elicits localized, mucosal IgA immunity in rhesus macaques correlated with delayed acquisition following a repeated low-dose rectal SIV(mac251) challenge. J Virol 2012;86:4644-4657.
257. Letvin NL, et al. Immune and genetic correlates of vaccine protection against mucosal infection by SIV in monkeys. Sci Transl Med 2011;3:81ra36.
258. Flatz L, et al. Gene-based vaccination with a mismatched envelope protects against simian immunodeficiency virus infection in nonhuman primates. J Virol 2012;86:7760-7770.
259. Banks ND, Kinsey N, Clements J, Hildreth JE. Sustained antibody-dependent cell-mediated cytotoxicity (ADCC) in SIV-infected macaques correlates with delayed progression to AIDS. AIDS Res Hum Retroviruses 2002;18:1197-1205.
260. Gomez-Roman VR, et al. Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J Immunol 2005;174:2185-2189.
261. Florese RH, et al. Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines. J Immunol 2009;182:3718-3727.
262. Overbaugh J, Morris L. The antibody response against HIV-1. Cold Spring Harb Perspect Med 2012;2:a007039.
263. Sant AJ, McMichael A. Revealing the role of CD4(+) T cells in viral immunity. J Exp Med 2012;209:1391-1395.
264. Soghoian DZ, et al. HIV-specific cytolytic CD4 T cell responses during acute HIV infection predict disease outcome. Sci Transl Med 2012;4:123ra125.
265. Soghoian DZ, Streeck H. Cytolytic CD4(+) T cells in viral immunity. Expert Rev Vaccines 2010;9:1453-1463.
266. Ranasinghe S, et al. HIV-specific CD4 T cell responses to different viral proteins have discordant associations with viral load and clinical outcome. J Virol 2012;86:277-283.
267. Zhou Y, et al. Dominance of the CD4(+) T helper cell response during acute resolving hepatitis A virus infection. J Exp Med 2012;209:1481-1492.
268. Klatt NR, Silvestri G. CD4+ T cells and HIV: a paradoxical Pas de Deux. Sci Transl Med 2012;4:123ps124.
269. Gloster SE, et al. Association of strong virus-specific CD4 T cell responses with efficient natural control of primary HIV-1 infection. AIDS 2004;18:749-755.
270. Zheng N, Fujiwara M, Ueno T, Oka S, Takiguchi M. Strong ability of Nef-specific CD4+ cytotoxic T cells to suppress human immunodeficiency virus type 1 (HIV-1) replication in HIV-1-infected CD4+ T cells and macrophages. J Virol 2009;83:7668-7677.